+ Site Statistics
References:
52,572,879
Abstracts:
28,705,754
PMIDs:
27,750,366
DOIs:
25,464,004
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Urokinase-type plasminogen activator, its inhibitor and cathepsin D predict prognosis in node negative breast cancer



Urokinase-type plasminogen activator, its inhibitor and cathepsin D predict prognosis in node negative breast cancer



Proceedings of the American Association for Cancer Research Annual Meeting 35: 201




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034144275

Download citation: RISBibTeXText


Related references

Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients. Anticancer Research 29(5): 1475-1482, 2009

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. Journal of the National Cancer Institute 93(12): 913-920, 2001

Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator. Clinical Breast Cancer 8(2): 168-177, 2008

The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer. International Journal of Biological Markers 19(4): 282-288, 2005

Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: An immunohistochemical study of prognostic value and relations to tenascin-C and other factors. British Journal of Cancer 80(1-2): 167-174, 1999

The complex between urokinase plasminogen activator and its type-1 inhibitor denotes poor disease outcome in 576 node-negative breast cancer patients. EJC Suppl.s 2(3): 173, 2004

Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clinical Cancer Research 4(1): 177-182, 1998

Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease. Annals of Surgical Oncology 10(8): 948-953, 2003

Urokinase plasminogen activator and its type-1 inhibitor are superior to the Nottingham Prognostic Index NPI in predicting relapse in node-negative breast cancer patients. Breast Cancer Research & Treatment 64(1): 40, 2000

Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. Bmc Cancer 8: 194, 2008

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. Breast Cancer Research & Treatment. 49(1): 41-50,, 1998

Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Research & Treatment. 47(1): 9-16,., 1998

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 for tumor-biological risk assessment in node-negative breast cancer patients The multicenter trial NNBC 3-Europe. European Journal of Cancer Suppl.s 6(7): 188-189, 2008

Urokinase-type plasminogen activator , urokinase-type plasminogen activator receptor , plasminogen activator inhibitor type 1 , type 2 , and tissue-type plasminogen activator in breast cancer cells. Fibrinolysis & Proteolysis 14(Suppl. 1): 38, 2000

Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Cancer 101(3): 486-494, 2004